[{"indications": "Indications\u00a0%s\n(From 8.1.1 Alkylating drugs: British National Formulary)\nBusulfan is given by mouth to treat chronic myeloid leukaemia. Busulfan given by mouth or intravenously, followed by cyclophosphamide, is also licensed as conditioning treatment before haematopoietic stem-cell transplantation in adults and children. Frequent blood tests are necessary because excessive myelosuppression may result in irreversible bone-marrow aplasia. Rarely, progressive pulmonary fibrosis is associated with busulfan. Skin hyperpigmentation is a common side-effect of oral therapy.", "name": "BUSULFAN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.1 Cytotoxic drugs", "8.1.1 Alkylating drugs", "BUSULFAN"], "cautions": "Cautions\u00a0see section 8.1 and notes above; monitor cardiac function; previous radiation therapy; avoid in acute\r\nporphyria (but see section 9.8.2); interactions: Appendix 1\r\n(busulfan)", "side-effects": "Side-effects\u00a0see section 8.1 and notes above; also hepatotoxicity (including\r\nhepatic veno-occlusive disease, hyperbilirubinaemia, jaundice and\r\nfibrosis); cardiac tamponade in thalassaemia; pneumonia; skin hyperpigmentation", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4679.htm", "doses": ["Chronic myeloid leukaemia, induction of remission, by mouth, 60\u00a0micrograms/kg daily (max. 4\u00a0mg); maintenance,\r\nusually 0.5\u20132\u00a0mg daily", "Conditioning treatment before haematopoietic stem-cell\r\ntransplantation, by mouth or  by intravenous infusion, consult product literature"], "pregnancy": "Pregnancy\u00a0avoid (teratogenic in animals);\r\nmanufacturers advise effective contraception during and for 6 months\r\nafter treatment in men or women; see also Pregnancy and Reproductive\r\nFunction"}]